Home - News ( United States | United Kingdom | Italy | Germany ) - Football scores

Showing content from http://www.ncbi.nlm.nih.gov/pubmed/15150206 below:

Pharmacy benefits and the use of drugs by the chronically ill

Affiliations

• ¹ RAND, Santa Monica, Calif 90407-2138, USA. dgoldman@rand.org

• PMID: 15150206
• DOI: 10.1001/jama.291.19.2344

Item in Clipboard

Dana P Goldman et al. JAMA. 2004.

• ¹ RAND, Santa Monica, Calif 90407-2138, USA. dgoldman@rand.org

• PMID: 15150206
• DOI: 10.1001/jama.291.19.2344

Item in Clipboard

Context: Many health plans have instituted more cost sharing to discourage use of more expensive pharmaceuticals and to reduce drug spending.

Objective: To determine how changes in cost sharing affect use of the most commonly used drug classes among the privately insured and the chronically ill.

Design, setting, and participants: Retrospective US study conducted from 1997 to 2000, examining linked pharmacy claims data with health plan benefit designs from 30 employers and 52 health plans. Participants were 528,969 privately insured beneficiaries aged 18 to 64 years and enrolled from 1 to 4 years (960,791 person-years).

Main outcome measure: Relative change in drug days supplied (per member, per year) when co-payments doubled in a prototypical drug benefit plan.

Results: Doubling co-payments was associated with reductions in use of 8 therapeutic classes. The largest decreases occurred for nonsteroidal anti-inflammatory drugs (NSAIDs) (45%) and antihistamines (44%). Reductions in overall days supplied of antihyperlipidemics (34%), antiulcerants (33%), antiasthmatics (32%), antihypertensives (26%), antidepressants (26%), and antidiabetics (25%) were also observed. Among patients diagnosed as having a chronic illness and receiving ongoing care, use was less responsive to co-payment changes. Use of antidepressants by depressed patients declined by 8%; use of antihypertensives by hypertensive patients decreased by 10%. Larger reductions were observed for arthritis patients taking NSAIDs (27%) and allergy patients taking antihistamines (31%). Patients with diabetes reduced their use of antidiabetes drugs by 23%.

Conclusions: The use of medications such as antihistamines and NSAIDs, which are taken intermittently to treat symptoms, was sensitive to co-payment changes. Other medications--antihypertensive, antiasthmatic, antidepressant, antihyperlipidemic, antiulcerant, and antidiabetic agents--also demonstrated significant price responsiveness. The reduction in use of medications for individuals in ongoing care was more modest. Still, significant increases in co-payments raise concern about adverse health consequences because of the large price effects, especially among diabetic patients.

PubMed Disclaimer

• Employer drug benefit plans and spending on prescription drugs.

  Joyce GF, Escarce JJ, Solomon MD, Goldman DP. Joyce GF, et al. JAMA. 2002 Oct 9;288(14):1733-9. doi: 10.1001/jama.288.14.1733. JAMA. 2002. PMID: 12365957

• Adverse events associated with prescription drug cost-sharing among poor and elderly persons.

  Tamblyn R, Laprise R, Hanley JA, Abrahamowicz M, Scott S, Mayo N, Hurley J, Grad R, Latimer E, Perreault R, McLeod P, Huang A, Larochelle P, Mallet L. Tamblyn R, et al. JAMA. 2001 Jan 24-31;285(4):421-9. doi: 10.1001/jama.285.4.421. JAMA. 2001. PMID: 11242426

• Impact of cost sharing on prescription drugs used by Medicare beneficiaries.

  Goedken AM, Urmie JM, Farris KB, Doucette WR. Goedken AM, et al. Res Social Adm Pharm. 2010 Jun;6(2):100-9. doi: 10.1016/j.sapharm.2010.03.003. Epub 2010 May 7. Res Social Adm Pharm. 2010. PMID: 20511109

• Approaches to pharmacy benefit management and the impact of consumer cost sharing.

  Olson BM. Olson BM. Clin Ther. 2003 Jan;25(1):250-72. doi: 10.1016/s0149-2918(03)90035-x. Clin Ther. 2003. PMID: 12637125 Review.

• [Can linking co-payment for drugs to evidence on treatment value improve health outcomes and contain healthcare costs?].

  Triki N, Pliskin JS, Greenberg D. Triki N, et al. Harefuah. 2010 Aug;149(8):524-8, 550. Harefuah. 2010. PMID: 21341433 Review. Hebrew.

• Exenatide therapy and the risk of pancreatitis and pancreatic cancer in a privately insured population.

  Romley JA, Goldman DP, Solomon M, McFadden D, Peters AL. Romley JA, et al. Diabetes Technol Ther. 2012 Oct;14(10):904-11. doi: 10.1089/dia.2012.0075. Epub 2012 Jul 30. Diabetes Technol Ther. 2012. PMID: 22845701 Free PMC article.

• "You Have to Rob Peter to Pay Paul So Your Kid Can Breathe": Using Qualitative Methods to Characterize Trade-Offs and Economic Impact of Asthma Care Costs.

  Galbraith AA, Faugno E, Cripps LA, Przywara KM, Wright DR, Gilkey MB. Galbraith AA, et al. Med Care. 2023 Dec 1;61(12 Suppl 2):S95-S103. doi: 10.1097/MLR.0000000000001914. Epub 2023 Nov 9. Med Care. 2023. PMID: 37963027 Free PMC article.

• How patient cost-sharing trends affect adherence and outcomes: a literature review.

  Eaddy MT, Cook CL, O'Day K, Burch SP, Cantrell CR. Eaddy MT, et al. P T. 2012 Jan;37(1):45-55. P T. 2012. PMID: 22346336 Free PMC article.

• Should national pharmacare apply a value-based insurance design?

  Yeung K, Morgan SG. Yeung K, et al. CMAJ. 2019 Jul 22;191(29):E811-E815. doi: 10.1503/cmaj.181721. CMAJ. 2019. PMID: 31332049 Free PMC article. No abstract available.

• Prescription drug cost sharing: associations with medication and medical utilization and spending and health.

  Goldman DP, Joyce GF, Zheng Y. Goldman DP, et al. JAMA. 2007 Jul 4;298(1):61-9. doi: 10.1001/jama.298.1.61. JAMA. 2007. PMID: 17609491 Free PMC article. Review.

RetroSearch is an open source project built by @garambo | Open a GitHub Issue

Search and Browse the WWW like it's 1997 | Search results from DuckDuckGo

HTML: 3.2 | Encoding: UTF-8 | Version: 0.7.3